[Guideline for therapy of malignant thyroid tumours: pleading for an actualization].
Total (or near total) thyroidectomy (TE) followed by radioiodine ((131)I) ablation (RIA) of residual thyroid tissue is considered to be the ideal treatment for differentiated thyroid carcinoma. However, the actual guideline of the DGN (German Society of Nuclear Medicine) recommends for the so-called papillary micro-carcinoma of the thyroid (PMC) no further therapeutic strategy (no complete TE, no (131)I-ablation of the remaining lobe). PMC has been defined as papillary carcinoma measuring 1 cm (T1) in maximal diameter according to the World Health Organization classification system for thyroid tumours (1988). The new WHO-classification (starting in 2003) defines the T1-tumour measuring 2 cm in maximal diameter. The authors demand a new, modern guideline, following the new WHO classification. This includes, that despite the overall excellent prognosis for patients with PMC, the treatment of patients with T1-tumours of the new WHO-classification (including the "old" PMC) should be no different from the treatment of patients with conventional papillary thyroid carcinoma, i.e. complete surgery (TE and central lymph node dissection) followed by RIA of residual thyroid tissue. The authors argue that it is not appropriate to consider the tumour size as the single most important key factor for therapy and prognosis. Even small tumours may have poor prognostic factors, such as lymph node metastasis, multifocality or molecular characteristics (expression of oncogenes).
Wieler
H
H
Nuklearmedizinische Abteilung, Bundeswehrzentralkrankenhaus, Städtischen Klinikum Kemperhof, Koblenz.
Bartenstein
P
P
Becker
H P
HP
Bell
E
E
Decker
P
P
Jacob
R
R
Kirsch
C M
CM
Musholt
T
T
Schwab
R
R
Schwerdtfeger
P
P
Trampert
L
L
D000075202:Contraindications; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D013964:Thyroid Neoplasms / Q000601:surgery / Q000628:therapy*; D013965:Thyroidectomy / Q000592:standards*